Nonmalignant Hematologic Disorders


Share

Program Content

Activities

  • Conference to Clinic Nonmalignant Hematology 2024
    CCO’s Conference to Clinic Highlights From ASH 2024 Annual Meeting: Classical Hematology
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 17, 2025

    Expires: July 16, 2025

Activities

Axatilimab Response Analysis
AGAVE-201 Response Analysis: Axatilimab for Patients With Chronic GVHD
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

Pimicotinib in cGVHD
Phase II Trial of Pimicotinib, a CSF-1R Inhibitor, for Previously Treated Chronic GVHD
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2024

Expires: December 09, 2025

LUNA 3: Rilzabrutinib in ITP
LUNA 3: Phase III Trial of Rilzabrutinib vs Placebo in Patients Aged ≥18 Yr With Persistent/Chronic Primary ITP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

VAYHIT3 Trial of Ianalumab
Phase II VAYHIT3 Interim Results: Ianalumab in Previously Treated Primary Immune Thrombocytopenia 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

ELA026 in sHLH
Phase Ib Study of ELA026, an Anti-SIRP-α/β/γ mAb, in Patients With Secondary Hemophagocyctic Lymphohistiocytosis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: December 12, 2025

Rovadicitinib in Chronic GVHD
Updated Results From a Phase Ib/IIa Trial of Rovadicitinib for Glucocorticoid-Refractory or Dependent Chronic Graft-vs-Host Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: December 15, 2025

Faculty

cover img faculity

Hanny Al-Samkari, MD

Classical Hematologist and Clinical Investigator
The Peggy S. Blitz Endowed Chair in Hematology/Oncology
Co-Director, Hereditary Hemorrhagic Telangiectasia Center
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Corey Cutler, MD, MPH

Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation